Acadia Pharmaceuticals is reporting tomorrow after the market close. Most of the analysts issued either 'Outperform' (8) or 'Buy' (2) recommendation and just 3 analysts said 'Hold'.Acadia's revenue is growing significantly and I think it will keep growing this quart a well, moreover, it might double compared to Q4'2016. According to Financial Times, revenue consensus is about $15.9M:If Acadia beats revenue, then it goes higher. EPS doesn't matter at the moment for them. Acadia will most likely go higher than $35 right after the earnings call.Agree or Disagree?